Table 4.
Adjusted means [95% confidence interval (CI)] for early developmental outcomes by quartile of urinary organophosphate flame retardant metabolite concentrations among 205 women undergoing 281 in vitro fertilization (IVF) cycles that had oocyte retrieval.
| Characteristic | BDCIPP | DPHP | ip-PPP | |
|---|---|---|---|---|
| trigger levels, pmol/L | ||||
| Q1 | 1,939 (1,766, 2,112) | 1,995 (1,821, 2,169) | 1,969 (1,794, 2,145) | 2,028 (1,855, 2,200) |
| Q2 | 2,163 (1,992, 2,333) | 2,061 (1,889, 2,233) | 2,120 (1,946, 2,293) | 2,097 (1,927, 2,267) |
| Q3 | 2,007 (1,838, 2,176) | 2,015 (1,842, 2,188) | 2,143 (1,970, 2,317) | 2,153 (1,985, 2,322) |
| Q4 | 2,123 (1,947, 2,299) | 2,155 (1980, 2,331) | 1,994 (1,817, 2,171) | 1,950 (1,773, 2,128) |
| p-trend | 0.26 | 0.25 | 0.99 | 0.71 |
| Total oocytes, count | ||||
| Q1 | 10.6 (9.6, 11.8) | 9.9 (8.9, 11.0) | 11.0 (9.9, 12.2) | 10.7 (9.6, 11.9) |
| Q2 | 11.1 (10.0, 12.3) | 11.4 (10.3, 12.7) | 11.1 (10.0, 12.3) | 10.9 (9.8, 12.1) |
| Q3 | 10.8 (9.8, 12.0) | 11.1 (10.0, 12.3) | 11.3 (10.2, 12.6) | 11.9 (10.7, 13.1) |
| Q4 | 11.5 (10.3, 12.8) | 11.7 (10.6, 13.0)* | 10.7 (9.6, 11.9) | 10.7 (9.5, 11.9) |
| p-trend | 0.34 | 0.04 | 0.69 | 0.68 |
| Total MII oocytes, count | ||||
| Q1 | 9.2 (8.2, 10.3) | 8.5 (7.6, 9.5) | 9.3 (8.3, 10.4) | 8.9 (7.9, 9.9) |
| Q2 | 9.4 (8.4, 10.5) | 9.4 (8.4, 10.5) | 9.5 (8.5, 10.6) | 9.3 (8.4, 10.4) |
| Q3 | 8.8 (7.9, 9.8) | 9.3 (8.3, 10.3) | 9.4 (8.4, 10.5) | 10.1 (9.1, 11.2) |
| Q4 | 9.6 (8.6, 10.7) | 9.8 (8.8, 10.9) | 8.8 (7.8, 9.9) | 8.6 (7.7, 9.7) |
| p-trend | 0.71 | 0.10 | 0.44 | 0.87 |
| Fertilization, proportion | ||||
| Q1 | 0.77 (0.72, 0.81) | 0.75 (0.70, 0.79) | 0.75 (0.70, 0.79) | 0.77 (0.72, 0.81) |
| Q2 | 0.72 (0.67, 0.76) | 0.73 (0.68, 0.77) | 0.68 (0.63, 0.73) | 0.75 (0.71, 0.79) |
| Q3 | 0.71 (0.66, 0.76) | 0.71 (0.66, 0.76) | 0.78 (0.73, 0.82) | 0.71 (0.66, 0.75) |
| Q4 | 0.70 (0.65, 0.74)* | 0.71 (0.66, 0.76) | 0.68 (0.63, 0.73)* | 0.65 (0.60, 0.70)* |
| p-trend | 0.04 | 0.27 | 0.17 | 0.0006 |
| Best quality embryos, count | ||||
| Q1 | 1.6 (1.3, 2.1) | 1.5 (1.1, 1.9) | 1.6 (1.2, 2.1) | 1.5 (1.1, 1.9) |
| Q2 | 1.5 (1.2, 2.0) | 1.3 (1.0, 1.7) | 1.4 (1.1, 1.9) | 1.8 (1.4, 2.3) |
| Q3 | 1.4 (1.0, 1.8) | 1.6 (1.3, 2.1) | 1.6 (1.3, 2.1) | 1.5 (1.2, 2.0) |
| Q4 | 1.5 (1.1, 1.9) | 1.5 (1.2, 2.0) | 1.4 (1.0, 1.8) | 1.2 (0.9, 1.6) |
| p-trend | 0.48 | 0.66 | 0.51 | 0.24 |
| Endometrial wall thickness, mm | ||||
| Q1 | 10.3 (9.79, 10.8) | 10.2 (9.7, 10.7) | 10.2 (9.7, 10.8) | 10.1 (9.6, 10.6) |
| Q2 | 10.3 (9.79, 10.8) | 10.2 (9.7, 10.7) | 10.2 (9.7, 10.7) | 10.1 (9.6, 10.6) |
| Q3 | 9.80 (9.31, 10.3) | 9.9 (9.4, 10.4) | 10.1 (9.6, 10.6) | 9.8 (9.3, 10.3) |
| Q4 | 9.94 (9.42, 10.5) | 10.0 (9.5, 10.5) | 9.8 (9.3, 10.3) | 10.3 (9.8, 10.8) |
| p-trend | 0.19 | 0.44 | 0.15 | 0.82 |
Note: Adjusted models control for maternal age (continuous), body mass index (continuous), race/ethnicity (black/Asian/other, white/Caucasian), year of IVF treatment cycle (continuous), and primary Society for Assisted Reproductive Technology (SART) infertility diagnosis at study entry (female, male, unknown). Adjusted means are presented for the mean maternal age (35.2), body mass index (24.0), race/ethnicity (white), year of IVF treatment cycle (2010), and primary SART infertility diagnosis at study entry (, ). BDCIPP, bis(1,3-dichloro-2-propyl) phosphate; DPHP, diphenyl phosphate; ip-PPP, isopropylphenyl phenyl phosphate; PFR, organophosphate flame retardant.
Significantly different from Q1 at the level.